| Zhao, Wei |
NCT05429723: First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383 |
|
|
| Recruiting | 1 | 32 | RoW | HS-10383, HS-10383 Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Cough | 06/22 | 06/22 | | |
NCT05339646: A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects |
|
|
| Recruiting | 1 | 108 | RoW | SSD8432 dose 1~7 and Ritonavir, SSD8432 dose 8~9, SSD8432 dose 10~12 and ritonavir, SSD8432 dose 13 and Ritonavir, SSD8432 dose 14 and Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Participants | 10/22 | 12/22 | | |
NCT05665647: Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants |
|
|
| Completed | 1 | 36 | RoW | Cohort 1: SIM0417/ritonavir and itraconazole, Interaction between SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Interaction between SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam, Interaction between SIM0417/ritonavir and midazolam | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Volunteers | 01/23 | 02/23 | | |
NCT05947097: A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment |
|
|
| Recruiting | 1 | 32 | RoW | HSK21542 Injection | Haisco Pharmaceutical Group Co., Ltd. | Renal Impairment | 07/23 | 12/23 | | |
NCT05826249: Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects |
|
|
| Recruiting | 1 | 20 | RoW | SIM0417/Ritonavir, 750 mg SIM0417/100 mg ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Elder | 09/23 | 11/23 | | |
NCT05731804: Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir |
|
|
| Not yet recruiting | 1 | 72 | RoW | SIM0417 600 mg; Ritonavir100 mg, SIM0417 375 mg; Ritonavir100 mg, SIM0417 750 mg; Ritonavir100 mg | Jiangsu Simcere Pharmaceutical Co., Ltd. | Renal Impairment, Hepatic Impairment | 12/23 | 12/23 | | |
NCT06092983: A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383 |
|
|
| Recruiting | 1 | 48 | RoW | HS-10383, HS-10383 Tablets, HS-10383 Placebo, HS-10383 Placebo Tablets | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Cough | 12/23 | 12/23 | | |
NCT06428903: Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose |
|
|
| Recruiting | 1 | 40 | RoW | ADC189 tablet, ADC189 granules, ADC189 180mg | Jiaxing AnDiCon Biotech Co.,Ltd | Healthy Volunteer | 07/24 | 07/24 | | |
NCT06313697: A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult |
|
|
| Recruiting | 1 | 132 | RoW | GR2102 injection, placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 01/25 | 12/25 | | |
NCT05777109: Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults |
|
|
| Recruiting | 1 | 180 | RoW | HS-20090, Recombinant human anti-RANKL monoclonal antibody injection, Xgeva®, Denosumab Injection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy | 04/24 | 04/24 | | |
NCT06536036: Evaluate the Effects of Food on the Pharmacokinetics of SIM0270 |
|
|
| Completed | 1 | 16 | RoW | SIM0270 | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Healthy Participants | 10/24 | 10/24 | | |
| Completed | 1 | 6 | RoW | [14C] HRS-5965 | Chengdu Suncadia Medicine Co., Ltd. | Complement Mediated Primary or Secondary Glomerular Diseases | 10/24 | 10/24 | | |
HRS-9231-103, NCT06657560: Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function |
|
|
| Recruiting | 1 | 40 | RoW | HRS-9231 | Shanghai Shengdi Pharmaceutical Co., Ltd | Contrast-Enhanced Magnetic Resonance Imaging Detection | 04/25 | 04/25 | | |
NCT06598956: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects |
|
|
| Not yet recruiting | 1 | 32 | RoW | TQ05105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 07/25 | 08/25 | | |
| Active, not recruiting | 1 | 6 | RoW | [14C] SIM0270 Oral Preparation | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Healthy Participants | 03/25 | 03/25 | | |
NCT06672276: To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency |
|
|
| Not yet recruiting | 1 | 32 | RoW | TQD3606 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria | 05/25 | 11/25 | | |
NCT06671873: Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects |
|
|
| Recruiting | 1 | 8 | RoW | 100 µCi [14C] HMPL-306, 100 µCi [14C] HMPL-306 suspension | Hutchmed | Mass Balance Study | 03/25 | 06/25 | | |
NCT06779253: A Study to Investigate the Effect of Pimicotinib on the Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 38 | RoW | pimicotinib capsules | Abbisko Therapeutics Co, Ltd | Healthy Subjects | 05/25 | 06/25 | | |
NCT05930704: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women |
|
|
| Recruiting | 1 | 45 | RoW | SHR-2017 injection, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Osteoporosis | 04/25 | 04/25 | | |
